HGH Fragment 176–191
₹15,000.00
About:
Modified GH Peptide · Targeted Lipolysis
HGH Fragment 176–191 is a stabilised analogue of the C-terminal end of Human Growth Hormone — specifically the amino acid sequence spanning positions 176 to 191. Peptigain supplies this compound as an isolated, precision-engineered fragment designed to amplify the fat-burning properties of full-length HGH while eliminating its insulin-antagonising and growth-promoting effects.
Unlike full HGH, Peptigain's Fragment 176–191 does not stimulate cell proliferation or IGF-1 production, making it distinct in its mechanism. Research demonstrates that it activates lipolysis more potently than native HGH and simultaneously inhibits lipogenesis — the formation of new fat. It is particularly studied for visceral and subcutaneous adipose tissue reduction without disrupting blood glucose levels.
For Research Use Only — Not for Human Administration
Quantity
Specifications: (HGH Fragment 176–191)
Type: Modified HGH C-Terminal Fragment
Sequence: AA 176–191
Purity: ≥98% HPLC Verified
Format: Lyophilised Powder
Key Research Areas:(HGH Fragment 176–191)
Targeted Lipolysis — Directly activates fat-burning pathways, particularly in adipose tissue depots
No Insulin Disruption — Does not elevate blood glucose, unlike full HGH
Anti-Lipogenic — Inhibits new fat cell formation, studied for long-term body composition research
Muscle Preservation — Research suggests lean tissue is maintained even during caloric restriction